

Ref: EPL/CS/SE/0081/2025

Date: October 17, 2025

To,

National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051	BSE Limited P J Towers, Dalal Street, Mumbai- 400 001
Script Symbol: EMCURE	Scrip Code/Symbol: 544210/ EMCURE

Dear Sir/Madam,

Subject: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Revision in Credit Rating

Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we wish to inform that CRISIL Ratings Limited ("CRISIL"), has upgraded and re-affirmed its ratings on the bank loan facilities of Emcure Pharmaceuticals Limited, as under:

Facilities	Amount (Rs. in Crores)	Type of Rating	Rating	Rating Action
Bank Loan Facilities	1957.5	Long Term Rating	CRISIL AA-/Positive	Upgraded from 'CRISIL AA-/ Stable'
		Short Term Rating	CRISIL A1+	Re-affirmed at CRISIL A1+

You are requested to take the above information on your records.

Thanking you,

For **Emcure Pharmaceuticals Limited****Chetan Sharma**
Company Secretary & Compliance Officer**Emcure Pharmaceuticals Limited**

Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

Phone Nos.: +91 20 – 35070033/ 35070000 Fax No.: +91 20 3507 0060

E-mail: corporate@emcure.com Website: www.emcure.com CIN: L24231PN1981PLC024251